Multiple drug resistance in Candida albicans

R Prasad1, S K Murthy, V Gupta

  • 1School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.

Acta Biochimica Polonica
|January 1, 1995
PubMed

Insights

Researchers identified the Candida Drug Resistance (CDR 1) gene, which confers multidrug resistance by encoding an ABC superfamily membrane pump. This finding advances understanding of drug resistance mechanisms in fungi.

Area of Science:

  • Molecular Biology
  • Mycology
  • Biochemistry

Background:

  • Pleiotropic drug resistance (PDR) genes are crucial for fungal survival against toxic compounds.
  • Understanding multidrug resistance mechanisms in pathogenic fungi like Candida albicans is vital for effective treatment.

Purpose of the Study:

  • To clone and characterize a novel multidrug resistance gene from Candida albicans.
  • To investigate the functional role of the identified gene in conferring resistance to various drugs.

Main Methods:

  • Functional complementation of a Saccharomyces cerevisiae PDR5 null mutant.
  • Gene sequencing and nucleotide analysis.
  • Protein structure prediction using bioinformatics tools.

Main Results:

  • Cloning and sequencing of the Candida Drug Resistance (CDR 1) gene.
  • CDR 1 confers resistance to cycloheximide, chloramphenicol, and other unrelated drugs when expressed in a sensitive host.
  • CDR 1 encodes a putative ABC superfamily transporter with a characteristic bipartite structure.

Conclusions:

  • CDR 1 is a functional multidrug resistance gene in Candida species.
  • The identified transporter shares structural similarities with known PDR proteins.
  • Evidence suggests the presence of multiple PDR homologues in Candida albicans with distinct resistance profiles.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...